BD introduces disposable injection pen
FRANKLIN LAKES, N.J. — Medical supply company BD has introduced a disposable injection pen that it said was designed for drugs requiring frequent, low-volume injections or variable dosing.
The company’s BD Medical division announced the introduction of the Vystra, which it will showcase at the 2012 Parenteral Drug Association meeting in Las Vegas.
The company said the pen is designed for ease of use, comfort and reliability, including design features like multi-dosing, simple dose dialing and correction with audible clicks and large and clear dose markings.
"As more patient care shifts to the outpatient setting, self-injection devices must be able to accommodate the requirements of an ever broader range of drugs and patient profiles," BD Medical VP and global leader for pharmaceutical systems and the self-administration injection systems platform. "With the BD Vystra disposable pen, BD has incorporated several customization options to meet these needs, such as variable or fixed dosing and multiple look-and-feel designs. This ability to customize the device introduces a new level of flexibility for drug manufacturers."
FDA approves Sandoz dermatology drug
PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Sandoz for treating symptoms of various skin diseases.
Sandoz, the generics arm of Swiss drug maker Novartis, announced the approval of desoximetasone ointment in the 0.25% strength. The drug is a generic version of Taro Pharmaceutical Industries’ Topicort and, according to Sandoz, is the first Fougera dermatology product Sandoz has launched since its $1.5 billion acquisition of the company in May 2012.
Topicort and its generic versions had sales of $36.5 million during the 12-month period that ended in August 2012, according to IMS Health.
FDA approves Celgene lung-cancer drug
SUMMIT, N.J. — The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.
Celgene announced the approval of Abraxane (paclitaxel) protein-bound particles for injectable suspension, for the first-line treatment of non-small cell lung cancer that has advanced locally or spread to other parts of the body, in combination with carboplatin, for patients who are not candidates for curative surgery or radiation therapy.
"Non-small cell is the most common type of lung cancer, the leading cause of cancer death in the United States," said Mark Socinski, director of the lung cancer section in the division of hematology and oncology at the University of Pittsburgh and lead investigator in the phase-2 and phase-3 clinical trials of the drug. "The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung cancer patients, in an area that has seen few treatment advancements in recent years."
According to the Centers for Disease Control and Prevention, more than 200,000 people were diagnosed with lung cancer, and more than 150,000 died from it. Non-small cell lung cancer, or NSCLC, accounts for 87% of lung cancer cases.